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Introduction
Contrary to expectations based on the immuno-compro-
mised clinical phenotype of the PNP-deficient patients,
the present study demonstrates that PNP inhibitors
(PNPi) can activate immune cells that can help mount a
robust antitumor response. PNP deficiency in humans
lead to elevation of plasma guanosine [1]. In the present
study, we demonstrate that guanosine can activate toll
like receptor 2 (TLR2) and TLR4. Powerful immune-sti-
mulatory properties of TLR2 and TLR4 agonist have
been exploited for their potential as anti-cancer agents
and as an adjuvant in cancer vaccines.
Method
TLR stimulation is tested in-vitro by assessing NF-B
activation in HEK293 cells expressing a given TLR. In
mouse melanoma model, cancer cells were injected sub-
cutaneously and treatment with the NTR001 was
initiated on day 6 after injection of tumor cells. Tumor
volume and survival were recorded every 3-4 days.
Mouse tetanus toxoid vaccine model was used to evalu-
ate the adjuvant effect of NTR001.
Results
Guanosine (100 uM) exhibits a significant stimulatory
effect on human TLR2 and TLR4 (p < 0.0001 vs vehi-
cle), alone and in combination with PNPi, NTR001 (10
uM). Guanosine demonstrates no effect on TLR3, TLR5,
TLR7, TLR8 and TLR9. NTR001 as single agent demon-
strates no effect on any of the TLRs. Treatment with
NTR001 at doses 30 mg/kg every other week given p.o.
and 5 mg/kg given every day in drinking water resulted
in a significant decrease in tumor volume compared to
the vehicle treated group (30 mg/kg and 5mg/kg p <
0.05 vs vehicle). Twenty percent of mice survived in the
5 mg/kg dose group whereas no mice survived in the
vehicle and 30 mg/kg dose groups. The immune poten-
tiating effect of NTR001 was further confirmed in
mouse tetanus toxoid model where it demonstrated
increase in both antibody titers and interferon-g levels.
Conclusion
PNP inhibitors represent a novel approach, to enhance
the immune system through activation of TLR2 and
TLR4, for the treatment of melanoma and other malig-
nancies. Combinations of NTR001 and/or guanosine
with other cancer immunotherapies such as checkpoint
modulators, CTLA-4 antagonist, PD-1 antagonist, and
IDO-1 inhibitors will be explored further.
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